Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review
Background and objective Recently, research on treatment intensification has gathered
momentum, and three novel therapy combinations were approved for metastatic castration …
momentum, and three novel therapy combinations were approved for metastatic castration …
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
K Fizazi, AA Azad, N Matsubara, J Carles, AP Fay… - Nature Medicine, 2024 - nature.com
Preclinical evidence has suggested an interplay between the androgen receptor, which
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …
largely drives the growth of prostate cancer cells, and poly (ADP-ribose) polymerase. This …
Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment
Y Hou, Z Zhao, P Li, Y Cao, Y Zhang, C Guo… - … et Biophysica Acta (BBA …, 2024 - Elsevier
The intractability and high mortality rate of castration-resistant prostate cancer (CRPC)
remain the most challenging problems in the field of prostate cancer (PCa). Emerging …
remain the most challenging problems in the field of prostate cancer (PCa). Emerging …
Xaluritamig, a STEAP1× CD3 XmAb 2+ 1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study
WK Kelly, DC Danila, CC Lin, JL Lee, N Matsubara… - Cancer Discovery, 2024 - AACR
Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)–
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …
targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such …
AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+ 1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer
O Nolan-Stevaux, C Li, L Liang, J Zhan, J Estrada… - Cancer Discovery, 2024 - AACR
The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate …
Summary Background [177 Lu] Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic
progression-free survival and overall survival in patients with metastatic castration-resistant …
progression-free survival and overall survival in patients with metastatic castration-resistant …
[PDF][PDF] Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance
BACKGROUND Metastatic hormone-sensitive prostate cancer (mHSPC) is androgen
dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal …
dependent, and its treatment includes androgen deprivation therapy (ADT) with gonadal …
De novo metastatic prostate cancer: Are we moving toward a personalized treatment?
C Piombino, M Oltrecolli, E Tonni, M Pirola, R Matranga… - Cancers, 2023 - mdpi.com
Simple Summary De novo metastatic hormone-sensitive prostate cancer usually has a
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
dismal prognosis, which has slightly improved in recent years thanks to the introduction of …
Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
DJ George, AK Morgans, N Constantinovici… - JAMA Network …, 2024 - jamanetwork.com
Importance Novel androgen receptor inhibitors (ARIs; darolutamide, enzalutamide, and
apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate …
apalutamide) are standard-of-care treatments for nonmetastatic castration-resistant prostate …
Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic
castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for …
castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for …